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Above-knee Prosthetic Femoropopliteal Bypass for Intermittent
Claudication. Results of the Initial and Secondary Procedures
S. Aune and E. Laxdal
Department of Surgery, Haukeland University Hospital, 5021 Bergen, Norway
Objectives: to report the results of primary and secondary prosthetic above-knee femoropopliteal bypass for intermittent
claudication.
Design: a retrospective study in a University hospital.
Patients: one hundred and twelve operations performed in 103 patients (26 women) between January 1990 and June
1997.
Methods: a comparison of primary assisted patency was made between Dacron and PTFE, between men and women and
between operations performed early and late in the study period. Patency of secondary procedures was also studied.
Results: there were no operative deaths. The 5-year survival rate was 81% and equal to that of a demographically
matched population. The primary assisted graft patency was 58% after two years. Women had a significantly better graft
patency than men (79% vs. 49%). The type of graft and the date of the operation did not influence the outcome. Forty
of the 55 occluded grafts were subjected to a redo procedure with a 1-year patency of 29%.
Conclusions: the results after prosthetic above-knee femoropopliteal bypass procedures are disappointing, and a controversy
persists as to whether this operation should be performed for intermittent claudication. The results of secondary procedures
are even worse, and perhaps should only be considered in patients suffering critical ischaemia.
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Introduction Patients and Methods
The treatment of intermittent claudication is con- One hundred and twelve above-knee femoropopliteal
troversial. The criteria for conservative treatment, bypass operations performed for intermittent clau-
endovascular treatment or surgical treatment have not dication on 103 patients between January 1990 and
been established.1 Likewise, no consensus exists on the June 1997 in a single vascular unit were studied. PTFE
best choice of conduit for above-knee femoropopliteal was used in the early years of the study period,
bypass. Several authors have reported acceptable whereas Dacron was used latterly. Postoperatively,
results with the use of a prosthetic graft.2–7 Others patients were given aspirin 160 mg daily on a per-
have advocated the use of autologous vein.8,9 If manent basis. Heart disease warranting treatment or
autologous vein is preferred, in situ vein and reversed causing symptoms was considered significant.
vein appear to give similar results.10,11 Secondary pro- Duplex scanning was performed at one, three, six
cedures are technically more demanding and the out- and twelve months and yearly thereafter. Significant
come of these procedures is less favourable, as (more than 50% diameter reduction) graft-related
compared to primary operations.12,13 stenotic lesions were treated, usually with endo-
We routinely use prosthetic conduits for above- vascular techniques. Graft occlusion was diagnosed
knee femoropopliteal bypass because they appear to on the basis of duplex scanning findings or symptoms.
function as well as vein grafts, they are readily avail- Every reintervention initiated new surveillance pro-
able and easy to use. The aim of the study is to decribe tocol.
the results of primary and secondary above-knee pros- Occluded grafts were opened selectively based on
thetic femoropopliteal bypass for intermittent clau- the level of symptoms and the general condition of
dication. the patient. No consideration was paid to the age of
the graft at the time of occlusion. Treatment comprised* Please address all correspondence to: S. Aune, Department of
Surgery, Haukeland University Hospital, 5021 Bergen, Norway. thrombolysis, surgical thrombectomy, or construction
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of a new bypass, depending on the individual cir-
cumstances. Patients in whom a stenotic lesion was
revealed after thrombolysis or thrombectomy were
treated with either percutaneous transluminal
angioplasty (PTA) or surgical revision, as an additional
procedure.
Operative mortality was defined as death within 30
days. Kaplan–Meier survival curves14 were based on
the index operation for the patients operated on more
than once. For comparison, the expected survival of a
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demographically matched population was calculated
from data provided by the Norwegian Central Bureau Fig. 1. The number of prosthetic above-knee femoropopliteal by-
passes performed for intermittent claudication each year during theof Statistics.15 The relative survival, defined as the ratio
study period (six months in 1997).of the observed survival to that of the expected, was
estimated.16
The assisted primary graft patency (i.e. primary
patency of grafts where interventions may have been
done on non-occluded grafts during follow-up) was
calculated with the product limit method for all the
procedures. A comparison was made between the two
types of conduit (PTFE and Dacron) and men and
women, and operations performed early (1990–1993)
and late (1994–1997) in the series.
The primary assisted patency of the first redo pro-
cedure was also studied. A comparison was made
between patients with intermittent claudication and
those with critical ischaemia as a result of graft oc-
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clusion. Critical ischaemia was defined as rest pain or
Fig. 2. Observed and expected survival of 103 patients with inter-gangrene.
mittent claudication operated on with prosthetic above-knee fem-
The Student’s t-test was applied to continuous data, oropopliteal bypass. The numbers below the curve indicate patients
at risk. ( . . . ) Expected survival; (–––) observed survival.Cox’s regression analysis was used to compare the
graft patency. The SPSS statistical software was used
either observed or relative survival. No differencefor statistical computations.
in survival could be demonstrated between patients
experiencing graft occlusion and those with per-
sistently open grafts.
The mean and median graft follow-ups were 28Results
months and 22 months, respectively (range: 1–95
months). The assisted primary graft patency at twoThe mean and median ages of all the patients were 68
years and 69 years, respectively (range 43–88 years). years was 58% (Fig. 3). Graft patency was not in-
fluenced by the conduit or by whether the operationThe 26 women (25%) were significantly older than the
men at the time of the index operation (mean age 71 was performed early or late in the series. Men and
women had a two-year graft patency of 49% and 79%,versus 67 years p<0.01). Of the 103 patients, 40 (39%)
had significant cardiac disease, 17 (16.5%) had diabetes respectively (p<0.05) (Fig. 4).
Fifty-five grafts occluded during follow-up, six dur-mellitus and 19 (18.5%) had a creatinine >125 lmol/l.
PTFE was used in 66 operations and Dacron in 46. ing the first 30 days. Fifteen grafts were managed
conservatively and none of these patients requiredThe number of operations performed annually is il-
lustrated in Fig. 1. subsequent amputation. Forty occluded grafts (in 36
patients) were either opened or replaced (Table 1).There were no operative deaths. The mean and
median follow-up were 48 months and 45 months, Twenty-two of these surgically treated cases had inter-
mittent claudication and eighteen had critical isch-respectively (range: 1–100 months). The 5-year survival
was 81%, which was similar to that of a demo- aemia as a result of the graft occlusion (Table 2).
The 40 limbs undergoing a secondary proceduregraphically matched population (Fig. 2). No significant
difference was noted between men and women in were submitted to a total number of 176 surgical
Eur J Vasc Endovasc Surg Vol 19, May 2000
S. Aune and E. Laxdal478
0 24
1.0
Months
G
ra
ft
 p
at
en
cy
0.2
0.3
0.4
0.6
6 12 18
0.7
0.8
0.9
0.5
0.1
92
83
64
0 12
1.0
Months
G
ra
ft
 p
at
en
cy
0.2
0.3
0.4
0.6
6
0.7
0.8
0.9
0.5
0.1
15
Fig. 3. Primary assisted patency of 112 prosthetic above-knee fem- Fig. 5. Primary assisted patency of 40 redo procedures performed
on patients with occluded prosthetic above-knee femoropoplitealoropopliteal bypass operations performed on patients with inter-
mittent claudication. The numbers below the curve indicate patients bypasses. The numbers below the curve indicate patients at risk.
at risk.
procedures, mean 4 (range 2–14) per patient. Nine of
the 40 redo procedures occluded within the first month,
and the 1-year patency rate was 29% (Fig. 5). There
was no difference in graft patency between the patients
who had intermittent claudication and those with
critical ischaemia following graft occlusion. Two
patients required amputation, and six required fasci-
otomy.
Discussion
Controversy regarding the indications for femo-
ropopliteal bypass in patients with intermittent clau-
dication may never be resolved. The decision-making
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process is complex and must be tailored to the in-Fig. 4. Primary assisted patency of prosthetic above-knee femoro-
dividual patient. Improvements in quality of life afterpopliteal bypass operations performed on men and women with
intermittent claudication. The numbers below the curve indicate successful surgery must be weighed against the lim-
patients at risk. (....) Women; (–––) men. itations of the procedure. Local factors such as the
availability of resources, and surgical expertise are
also important. This disparity in patient selection may
Table 1. Redo procedures after occlusion of 40 prosthetic above- explain the divergence of the reported results.2,4knee femoropopliteal bypasses.
In the present series patient demography and co-
Procedure Number morbidity are similar to those reported by others.2,17
PTFE was used as conduit early in the study periodThrombectomy 24
and Dacron was latterly used. This change of pref-Thrombectomy and patch 2
Thrombolysis 6 erence was merely due to the handling characteristics
Thrombolysis and PTA 3 of the two conduits.New bypass 5
The long-term survival of the patients in the present
series was similar to those of a demographically
matched population, whereas previous reports have
Table 2. Symptoms following occlusion of 40 prosthetic above- indicated a reduced survival for patients operated
knee femoropopliteal bypasses. on for intermittent claudication.2,18,19 However, our
patients were relatively old at the time of surgery,Symptoms Number
and a more favourable relative survival has been
Intermittent claudication 22 documented among older patients operated on for
Critical ischaemia 18
lower limb ischaemia.20
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Patients undergoing secondary procedures ex- to operate must be made on an individual basis, and
universal recommendations are difficult to give. Thehibited a long-term survival similar to those with
persistently open grafts. This was surprising, as we rather poor results following redo procedures propose
a conservative management of patients with in-have previously reported an inferior relative survival
of patients subjected to multiple vascular operations.21 termittent claudication due to occlusion of a prosthetic
femoropopliteal bypass.A two-year primary assisted patency rate of 58% is
similar to previous European reports, although
superior results usually are reported from the
U.S.2,17,22–24 Several authors have previously docu- References
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